[ad_1]
WHY: Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Apellis Pharmaceuticals, Inc. APLS resulting from allegations that Apellis may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Apellis securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=17734 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On July 17, 2023, the American Society of Retina Specialists issued a press release highlighting concerns with Syfovre, Apellis Pharmaceuticals’ new eye-disease drug. The release indicated that physicians have reported cases of eye inflammation in patients treated with the drug, including six instances of occlusive retinal vasculitis, a potentially blinding type of inflammation that blocks blood flow through the vessels that feed the retina.
On this news, the price of Apellis’ stock fell by $32.04 per share, or 37.92%, to close at $52.46 on July 17, 2023.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese…
[ad_2]
